Clinical Trial Update: Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating suramin for refractory or relapsed multiple myeloma or Castleman's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castleman Disease
• Multiple Myeloma

Drugs mentioned

• Suramin (suramin)

Snippet

Sponsor: University of Arkansas | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED